7GQ Stock Overview Develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Paragon 28, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Paragon 28 Historical stock prices Current Share Price US$10.20 52 Week High US$13.30 52 Week Low US$4.06 Beta 1.5 1 Month Change 9.09% 3 Month Change 117.95% 1 Year Change -1.92% 3 Year Change n/a 5 Year Change n/a Change since IPO -33.11%
Recent News & Updates
Paragon 28, Inc. Appoints Dave Demski to Board of Directors Dec 11
Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2023) Nov 14
Paragon 28, Inc. Raises Net Revenue Guidance for 2024 Nov 13
Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Paragon 28, Inc Nov 01
Johnson Fistel, LLP Announces Class Action Lawsuit Commencement on Behalf of Investors of Paragon 28, Inc Oct 25
Paragon 28, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 18 See more updates
Paragon 28, Inc. Appoints Dave Demski to Board of Directors Dec 11
Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2023) Nov 14
Paragon 28, Inc. Raises Net Revenue Guidance for 2024 Nov 13
Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Paragon 28, Inc Nov 01
Johnson Fistel, LLP Announces Class Action Lawsuit Commencement on Behalf of Investors of Paragon 28, Inc Oct 25
Paragon 28, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 18
Paragon 28, Inc. Launches the Phantom® Fibula Nail System for Less Invasive Fracture Repair Oct 17
Rosen Law Firm Files Securities Class Action Lawsuit Against Paragon 28, Inc Oct 01
Paragon 28, Inc. Launches the R3FLEX™? Stabilization System to Anatomically Repair Ankle Syndesmotic In Injury Sep 04
Paragon 28, Inc. Announces the Launch of SMART28 Case Management Portal Aug 14
Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2023) Aug 09 Paragon 28, Inc. Updates Revenue Guidance for the Full Year of 2024
Paragon 28, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 18
Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2024 May 10
First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2023) May 09
Paragon 28, Inc., Annual General Meeting, May 17, 2024 Apr 07
Paragon 28, Inc., Annual General Meeting, May 17, 2024 Apr 06 Paragon 28, Inc. to Report Q1, 2024 Results on May 08, 2024
Paragon 28, Inc. Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler®? R3INFORCE™? Extraosseous Repair System Mar 29
New major risk - Financial position Mar 27
Co-Founder recently bought €234k worth of stock Mar 20
Full year 2023 earnings released: US$0.58 loss per share (vs US$0.88 loss in FY 2022) Mar 01
Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Mar 01
Paragon 28, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 07
Paragon 28, Inc. Launches Precision®? Mis Bunion System Offering Surgeons A Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions Feb 02
Paragon 28, Inc. Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures Jan 31
New minor risk - Shareholder dilution Jan 28
Paragon 28, Inc. Launches the Mister Tendon™ Harvester System – the First and Only Minimally Invasive Harvesting System for Fhl and Fdl Tendon Transfer Procedures Jan 26
Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures Jan 17
Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 Jan 08
Paragon 28, Inc. Announce the Launch of the Grappler Knotless Anchor System and Bridgeline Tape Jan 05 Paragon 28, Inc. Launches Beast Cortical Fibers
Third quarter 2023 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2022) Nov 09
Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2023 Nov 08
New minor risk - Share price stability Oct 19
Paragon 28, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 18
Paragon 28®, Inc. Receives FDA Approval for Ide Feasibility Study of Its Smart Total Talus™ System for Use in Conjunction with the Apex 3D™ Total Ankle Replacement System Sep 12
New minor risk - Financial position Aug 04
Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022) Aug 03
Paragon 28, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 13
Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System May 24
Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc May 20
First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.12 loss in 1Q 2022) May 06
Paragon 28, Inc. Provides Revenue Guidance for the Year 2023 May 06
Full year 2022 earnings released: US$0.88 loss per share (vs US$0.26 loss in FY 2021) Mar 04
Paragon 28, Inc. to Report Q4, 2022 Results on Mar 02, 2023 Feb 17 Paragon 28, Inc. has completed a Follow-on Equity Offering in the amount of $110.5 million. Jan 26
Paragon 28, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full-Year Ended December 31, 2022 Jan 11
Paragon 28, Inc. Enters Settlement Agreement with Stryker Corp Dec 02
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 3Q 2021) Nov 12
Paragon 28, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year of 2022 Nov 11
Insider recently sold €1.1m worth of stock Nov 10
Paragon 28, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 28
Paragon 28, Inc. Announces Board Changes Aug 05
Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.05 loss in 2Q 2021) Aug 04 Paragon 28, Inc. Revises Revenue Guidance for the Full Year 2022
Paragon 28, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 19
Paragon 28, Inc.(NYSE:FNA) dropped from Russell 2500 Value Index Jun 26
Key Executive recently sold €355k worth of stock Jun 10
Paragon 28, Inc. Launches Monkey Rings™ Circular External Fixation System Jun 10
Key Executive recently sold €420k worth of stock Jun 02
Paragon 28, Inc. Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair May 20
First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.021 loss in 1Q 2021) May 11 Paragon 28, Inc. Provides Revenue Guidance for the Full Year 2022 May 10
High number of new directors May 02
Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair Apr 28
Paragon 28, Inc. Launches R3ACT™ Stabilization System for Ankle Injuries Apr 20
Paragon 28, Inc. to Report Q1, 2022 Results on May 09, 2022 Apr 19
Paragon 28, Inc. Announces Executive Changes Apr 15
High number of new directors Apr 06 Shareholder Returns 7GQ DE Medical Equipment DE Market 7D 6.3% 2.1% 2.0% 1Y -1.9% -7.9% 9.6%
See full shareholder returns
Return vs Market: 7GQ underperformed the German Market which returned 9.1% over the past year.
Price Volatility Is 7GQ's price volatile compared to industry and market? 7GQ volatility 7GQ Average Weekly Movement 14.2% Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 7GQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7GQ's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis.
Show more Paragon 28, Inc. Fundamentals Summary How do Paragon 28's earnings and revenue compare to its market cap? 7GQ fundamental statistics Market cap €870.56m Earnings (TTM ) -€54.26m Revenue (TTM ) €236.76m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7GQ income statement (TTM ) Revenue US$245.00m Cost of Revenue US$55.11m Gross Profit US$189.89m Other Expenses US$246.03m Earnings -US$56.15m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.67 Gross Margin 77.51% Net Profit Margin -22.92% Debt/Equity Ratio 79.3%
How did 7GQ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/07 22:16 End of Day Share Price 2025/01/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Paragon 28, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Craig Bijou BofA Global Research Neil Chatterji B. Riley Securities, Inc. Caitlin Cronin Canaccord Genuity
Show 7 more analysts 